Paradigm Biopharmaceuticals (Paradigm) (ASX:PAR) is a commercially-focused drug repurposing company.

We believe repurposing is the most optimal path to addressing an unmet need, and are taking a novel approach to developing effective, safe treatments for targeted clinical indications where there are currently limited options available to patients.

Adopting an intelligent and agile approach to clinical research and development, Paradigm’s experienced team is committed to the quality of the programmes.

Our immediate commercial focus is the repurposing of pentosan polysulfate sodium (iPPS, brand name Zilosul®) for the treatment of osteoarthritis (OA). This is a global unmet need and Paradigm has advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.

Paradigm is headquartered in Melbourne, Australia with offices in Europe and the US.


Our Mission

Paradigm Pharmaceuticals Limited (PAR) is a global biopharmaceutical company driven to improve patients’ lives through repurposing existing drugs and pioneering new solutions for unmet medical needs.

Our Values

Paradigm is always looking for people and partners who share our vision.

Belief in Repurposing

At Paradigm, we are dedicated to repurposing as a more cost-effective and accessible way of addressing some of the world’s unmet needs.

The reduction in the time, cost and risk associated with the clinical and commercial development pathway to taking new products to market is significant, and offers new avenues of hope for patients.

Paradigm’s primary focus is to repurpose pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS).

In OA, trials have already advanced into phase 3, and there are a potential 72m eligible candidates in key markets alone (US, EU5, AU, CAN). Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease-modifying potential.



Paradigm’s approach to market is driven by core competencies and significant experience at both board and executive level in clinical and commercial pharmaceutical development and the execution of clinical studies.

Strategic partners

Corporate Governance

Corporate governance policy

Corporate governance (CG) underpins the way Paradigm conducts business. We are committed to the highest level of governance and strive to foster a culture that values and rewards exemplary ethical standards, personal and corporate integrity and respect for others.

Whistle-blower policy

Our Whistle-blower (WB) policy sets out how Paradigm supports its team and partners so that they can safely express their concerns, know who to contact, how to make a report and the protections available to them.

Corporate governance statements

Our business operates in accordance with these Governance Documents.

Environment & social governance

At Paradigm we believe we have an obligation — to our employees, our investors, our partners and the environment — to operate our business safely and sustainably. Our management is responsible for enabling employees to contribute to our environmental objectives and to implement our Environment, Health and Safety Policy (EHS) policy.